Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002646 · ClinicalTrials.gov registry record · Phase 3
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
NCT00002646: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT00002646 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 1,500 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002646, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining chemotherapy with hormone therapy may kill more tumor cells. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of fenretinide may be an effective way to prevent the recurrence of breast cancer. It is not yet known whether tamoxifen plus fenretinide is more effective than tamoxifen alone for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen plus fenretinide with tamoxifen alone in treating postmenopausal women who have stage II or stage III breast cancer that is estrogen receptor positive and/or progesterone receptor positive.
Interventions
- DRUG tamoxifen citrate
- DRUG fenretinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 1995-10 |
| Phase | Phase 3 |
What the finished NCT00002646 record still lists
NCT00002646 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher).
The record links to 0 conditions, and to 2 interventions - of which tamoxifen citrate is the first listed.
NCT00002646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002646 about?
NCT00002646 is a clinical study titled "Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining chemotherapy with hormone therapy may kill more tumor cells. Chemoprevention therapy is the use of certain drugs to try to preven...
What is the current status of trial NCT00002646?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 1995-10.
What interventions are being tested in trial NCT00002646?
The interventions under investigation include: tamoxifen citrate (DRUG), fenretinide (DRUG).
Who is sponsoring clinical trial NCT00002646?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002646's enrollment target sits among peer trials
1,500 158th of 2000 higher than 1,838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia